The potential of TYRP1 as a therapeutic target has been explored previously in a phase 1 study evaluating the monoclonal antibody flanvotumab (IMC-20D7S), which showed that this treatment was well tolerated and had evidence of anti-tumor activity (16). This evidence concerns the gene TYRP1 and neoplasm.